Kala Bio (KALA) said Wednesday that Mark Iwicki has resigned as chief executive, effective immediately, but will continue to serve as board chair.
The clinical-stage biopharmaceutical company appointed President and Chief Operating Officer Todd Bazemore as interim CEO.
Kala Bio shares were down about 34% in recent trading.
Price: 7.11, Change: -3.77, Percent Change: -34.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.